{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

A survey to understand the overall treatment landscape of partial onset seizure with focus on lacosamide.

Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire
I. General / Demographics
  1. What is the average number of epilepsy patients you manage monthly in your clinical practice? *

  2. What is the average number of patients with focal-onset seizures (FOS) you manage monthly in your clinical practice? *

  3. In your clinical experience, which age group is most frequently diagnosed with focal-onset epilepsy? *

  4. What comorbidities are frequently associated with partial onset seizures in your patients? *
  5. What are the major challenges in managing partial onset seizures in Indian settings? *
    6. II. Lacosamide Usage Patterns (Dose, Initiation, Maintenance, Titration, Indications)
  6. What is your typical initial dose of lacosamide (LCM) as adjunctive for adult patients with FOS? *

  7. What is the typical duration required to titrate LCM to the therapeutic maintenance dose in adult patients with FOS? *

  8. What is the most common maintenance dose of LCM as adjunctive you prescribe for adult patients with FOS? *

  9. Describe the clinical characteristics of patients with FOS you consider ideal candidates for initiating LCM therapy. *
  10. How do you titrate LCM dose in elderly patients with FOS, including considerations for comorbidities (renal/hepatic impairment)? *
  11. In which clinical scenario do you most commonly administer intravenous (IV) LCM? *

  12. Under what conditions do you typically transition patients from IV to oral LCM? *
  13. How would you rate the transition of lacosamide from IV to oral LCM? *

  14. What are the primary factors influencing your decision to prescribe LCM for FOS? *
  15. In your treatment algorithm for focal epilepsy, where do you position LCM? *

  16. Do you prescribe lacosamide for partial onset seizures in pregnant women? *

  17. What is the maximum dose of lacosamide you prefer in patients with hepatic dysfunction? *
  18. What strategies do you employ to optimize patient adherence to LCM therapy in FOS management? *
  19. How would you rate patient adherence to LCM therapy based on your clinical experience? *

    20. III. Efficacy of Lacosamide
  20. Based on your clinical observations, how would you categorize the efficacy of LCM in achieving seizure control in patients with FOS? *

  21. In your experience, what is the typical time to observe a clinically meaningful response to adjunctive LCM therapy in patients with FOS? *

  22. What proportion of your patients with FOS achieve a clinically significant reduction in seizure frequency following LCM initiation? *

  23. How frequently do your patients achieve seizure freedom with LCM therapy? *

  24. In your clinical practice how does LCM compare to first-generation antiseizure medications (ASMs) in the management of FOS in terms of efficacy and safety? *
  25. Which ASM, when combined with LCM, demonstrates the most significant synergistic effect in controlling FOS? Please specify and describe the observed clinical benefit. *
  26. How effective is LCM in reducing seizure frequency within the first 3 months of therapy in your patients with FOS? *

  27. Does adjunctive LCM therapy allow for dose reduction of concomitant first-line ASMs in your patients? *

  28. How does LCM add-on therapy impact the frequency of seizure-related hospital admissions in your patients with FOS? *

  29. How frequently do your patients report an improved quality of life following LCM initiation? *

  30. What is the overall patient satisfaction with LCM regarding seizure control and tolerability? *

  31. How would you describe the efficacy and tolerability of lacosamide (LCM) compared to other antiseizure medications (ASMs) when used as a first add-on therapy in the management of focal-onset seizures (FOS)? *
  32. How effective is LCM as 1st add-on to incomplete response in FOS patients? *

  33. How effective is LCM in managing drug-resistant FOS in your clinical practice? *

  34. How effective do you find lacosamide as an add-on therapy in focal onset seizures? *

    35. IV. Safety of Lacosamide
  35. Do you observe any common adverse effects of lacosamide? If yes, what are the most frequent adverse effects you encounter? *
  36. How does the severity of LCM-related adverse effects compare to other ASMs in your experience? *

  37. Compared to levetiracetam, how does LCM perform in terms of cognitive adverse effects in your patients with FOS? *

  38. How does LCM compare to other ASMs in terms of drug-drug interactions? *

    39. V. Tolerability / Cognitive Effects
  39. How would you rate the overall tolerability of LCM in patients with FOS? *

  40. When LCM is added to levetiracetam, does it mitigate behavioral adverse effects in your patients? *

  41. How would you rate the cognitive side effect profile of lacosamide compared to other anti-seizure medications? *

  42. How does LCM’s cognitive adverse effect profile compare to other ASMs in your experience? *